US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 11:30:54 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:A Canadian serial killer who brought victims to a pig farm is hospitalized after a prison assault
Next:I hoarded so many items people called me 'Skip Man' and I was scared to walk around my house
You may also like
- Fake elector case: Former Arizona GOP chair Kelli Ward and others set to be arraigned
- New Year Honours: New Zealanders recognised for acting, saving lives, writing hymns and more
- Roberto Cavalli: Italian fashion designer dies aged 83
- Ukraine lowers conscription age after drop in volunteers to fight Russian invasion
- Brewers right
- Six months into Gaza war, Israel faces deepening isolation
- Tākaka man who died in mysterious circumstances named
- Christopher Luxon's reo Māori lessons paid for by taxpayer
- Microsoft's AI chatbot will remember everything you do on a PC